Anteris Technologies Global Corp. (AVR) Price & Analysis

Compare

42 Followers

AVR Stock Chart & Stats

$5.93

-$0.12(-2.09%)

At close: Jan 08 4:00 PM EST

$5.93

-$0.12(-2.09%)

Day’s Range― - ―

52-Week Range$2.34 - $8.79

Previous Close$5.88

Volume157.53K

Average Volume (3M)171.58K

Market Cap

$192.39M

Enterprise Value$155.17M

Total Cash (Recent Filing)$9.12M

Total Debt (Recent Filing)$2.35M

Price to Earnings (P/E)―

Beta2.09

Next Earnings

Mar 18, 2026

EPS Estimate

-0.56

Next Dividend Ex-DateN/A

Dividend YieldN/A

Share Statistics

EPS (TTM)-0.62

Shares Outstanding41,197,570

10 Day Avg. Volume100,039

30 Day Avg. Volume171,577

Financial Highlights & Ratios

PEG Ratio>-0.01

Price to Book (P/B)1.80

Price to Sales (P/S)41.81

P/FCF Ratio-1.78

Enterprise Value/Market Cap0.81

Enterprise Value/Revenue72.54

Enterprise Value/Gross Profit106.77

Enterprise Value/Ebitda-1.83

Forecast

1Y Price Target

$17.50

Price Target Upside195.11% Upside

Rating ConsensusModerate Buy

Number of Analyst Covering2

EPS Forecast (FY)-2.24

Revenue Forecast (FY)$2.47M

Bulls Say, Bears Say

Bulls Say

Clinical Trial SuccessThe DurAVR system demonstrated stellar one-year hemodynamic outcomes as well as safety and efficacy results, with single-digit gradients and no paravalvular leak.

Market DifferentiationThe hierarchical analysis is powered to demonstrate superiority for DurAVR over the Sapien platform and the Evolut system, providing deeper comparisons versus incumbent commercial TAVR devices.

Regulatory AdvancementsThe FDA issued IDE approval for the PARADIGM PMA trial, which will allow the company to move toward initiation of enrollment in the US.

Bears Say

Anteris Technologies Global Corp. News

Anteris Technologies files to sell 9.1M shares of common stock for holders

16:36 EST Anteris Technologies (AVR) files to sell 9.1M shares of common stock for holders Published first on...

10d ago

AVR

Anteris Technologies Presents Data from 100 DurAVR(R) THV Patients at PCR London

Anteris Technologies (AVR) released 30-day clinical outcomes for the DurAVR THV in one hundred severe aortic stenosis patients...

20d ago

AVR

Anteris Technologies Holds Annual Stockholders Meeting

Anteris Technologies Global Corp. ( ($AVR) ) has issued an update. On December 3, 2025, Anteris Technologies Global...

3d ago

AVR

Anteris Technologies Ends Agreement with 4C Medical

Anteris Technologies Global Corp. ( ($AVR) ) has shared an announcement. On November 26, 2025, Anteris Technologies Global...

5d ago

AVR

Anteris Technologies Reports Q3 2025 Progress and Financials

Anteris Technologies Global Corp. ( ($AVR) ) has released its Q3 earnings. Here is a breakdown of the...

13d ago

AVR

Promising Potential of Anteris Technologies’ DurAVR System Justifies Buy Rating

In a report released today, Josh Jennings from TD Cowen reiterated a Buy rating on Anteris Technologies Global...

20d ago

AVR

Anteris Technologies Reports Positive DurAVR® THV Outcomes

Anteris Technologies Global Corp. ( ($AVR) ) has shared an update. On November 16, 2025, Anteris Technologies Global...

20d ago

AVR

Anteris Technologies: Strategic Advancements and FDA Approval Bolster Buy Rating

Anteris Technologies Global Corp., the Healthcare sector company, was revisited by a Wall Street analyst yesterday. Analyst Josh...

1M ago

AVR

Anteris Technologies Receives FDA Approval for PARADIGM Trial

An announcement from Anteris Technologies Global Corp. ( ($AVR) ) is now available. On November 3, 2025, Anteris...

1M ago

AVR

Anteris Technologies receives FDA approval to initiate PARADIGM trial

Anteris announced it has received U.S. Food and Drug Administration, FDA, approval to initiate PARADIGM, its global Investigational...

1M ago

AVR

Promising Investment Opportunity: Anteris Technologies’ DurAVR Platform Showcases Outstanding Clinical Outcomes

TD Cowen analyst Josh Jennings maintained a Buy rating on Anteris Technologies Global Corp. today and set a...

1M ago

AVR

Anteris Technologies reports clinical outcomes for DurAVR THV in patients

Anteris Technologies (AVR) Global announced one-year clinical outcomes for the DurAVR Transcatheter Heart Valve, or THV, in symptomatic...

1M ago

AVR

Anteris Technologies Begins Global PARADIGM Trial Enrollment

The latest update is out from Anteris Technologies Global Corp. ( ($AVR) ). On October 27, 2025, Anteris...

1M ago

AVR

Anteris Technologies treats first patient in DurAVR heart valve pivotal trial

Anteris Technologies (AVR) announced the first patients have been enrolled and successfully treated in the DurAVR Transcatheter Heart...

1M ago

AVR

AVR FAQ

What was Anteris Technologies Global Corp.’s price range in the past 12 months?

Anteris Technologies Global Corp. lowest stock price was $2.34 and its highest was $8.79 in the past 12 months.

What is Anteris Technologies Global Corp.’s market cap?

Anteris Technologies Global Corp.’s market cap is $192.39M.

When is Anteris Technologies Global Corp.’s upcoming earnings report date?

Anteris Technologies Global Corp.’s upcoming earnings report date is Mar 18, 2026 which is in 101 days.

How were Anteris Technologies Global Corp.’s earnings last quarter?

Anteris Technologies Global Corp. released its earnings results on Nov 12, 2025. The company reported -$0.62 earnings per share for the quarter, missing the consensus estimate of -$0.542 by -$0.078.

Is Anteris Technologies Global Corp. overvalued?

According to Wall Street analysts Anteris Technologies Global Corp.’s price is currently Undervalued. Get more investment ideas with TipRanks Premium

Does Anteris Technologies Global Corp. pay dividends?

Anteris Technologies Global Corp. does not currently pay dividends.

What is Anteris Technologies Global Corp.’s EPS estimate?

Anteris Technologies Global Corp.’s EPS estimate is -0.56.

How many shares outstanding does Anteris Technologies Global Corp. have?

Anteris Technologies Global Corp. has 41,197,570 shares outstanding.

What happened to Anteris Technologies Global Corp.’s price movement after its last earnings report?

Anteris Technologies Global Corp. reported an EPS of -$0.62 in its last earnings report, missing expectations of -$0.542. Following the earnings report the stock price went down -2.571%.

Which hedge fund is a major shareholder of Anteris Technologies Global Corp.?

Currently, no hedge funds are holding shares in AVR

Anteris Technologies Global Corp. Stock Smart Score

Neutral

Fundamentals

Return on Equity

-2462.70%

Trailing 12-Months

Asset Growth

-9.61%

Trailing 12-Months

Top Smart Score Stocks >

Company Description

Anteris Technologies Global Corp.

Anteris Technologies Global Corp. (AVR) is an innovative biotechnology company specializing in the development of advanced therapeutic solutions for various medical conditions. The company focuses on sectors such as cardiovascular health and regenerative medicine, offering products that utilize its proprietary technologies. Anteris is dedicated to improving patient outcomes through its pipeline of medical devices and therapies that enhance healing and recovery processes.

Anteris Technologies Global Corp. (AVR) Earnings & Revenues

Historic Earnings Reports

AVR Stock 12 Month Forecast

Average Price Target

$17.50

▲(195.11% Upside)

{"navigator":{"disabled":true},"exporting":{"enabled":false},"title":{"text":null},"chart":{"height":200,"style":{"fontFamily":"Roboto Flex, -apple-system, BlinkMacSystemFont, Segoe UI, Roboto, Helvetica, Arial, sans-serif, Apple Color Emoji, Segoe UI Emoji, Segoe UI Symbol","fontWeight":"400","color":"#5d5d5e"},"spacingTop":30,"spacingRight":60,"events":null},"yAxis":{"labels":{"style":{"color":"inherit"},"distance":6,"x":-6,"y":-6,"zIndex":1,"map_label_formatter":{"2":"$2","21":"$21","6.75":"$6.75","11.5":"$11.5","16.25":"$16.25"}},"plotLines":[{"color":"rgba(0,0,0,0)","value":20,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":-10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-bottom flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#199ca5\">High </span>\n\n  <span style=\"color:#199ca5\">$20.00</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":17.5,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":0,"text":"<div  class=\"positionrelative hoverZ3 triangleleft flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#828080\">Average </span>\n\n  <span style=\"color:#828080\">$17.50</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":15,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-top flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#912767\">Low </span>\n\n  <span style=\"color:#912767\">$15.00</span>\n  </div></div>","useHTML":true}}],"tickPositions":[2,6.75,11.5,16.25,21],"lineColor":"#dddddd","gridLineWidth":1,"gridLineColor":"#dddddd","lineWidth":1,"title":{"text":""}},"plotOptions":{"series":{"states":{"inactive":{"opacity":1}}},"line":{"animation":{"duration":0},"dataLabels":{"allowOverlap":true},"borderWidth":1,"marker":{"enabled":true,"fillColor":"#FFFFFF","radius":3,"lineWidth":2,"symbol":"circle","lineColor":"#828080"}}},"xAxis":{"labels":{"style":{"color":"inherit"},"rotation":0,"map_label_formatter":{"3":"Nov<br/>2024","6":"Jan<br/>2025","9":"Jun<br/>2025","12":"Nov<br/>2025","25":"Nov<br/>2026"}},"tickPositions":[3,6,9,12,25],"plotLines":[{"color":"#dddddd","width":1,"value":12},{"color":"#dddddd","width":1,"value":12}],"lineWidth":0,"gridLineWidth":1,"gridLineColor":"#dddddd","tickLength":0},"legend":{"symbolRadius":0,"symbolPadding":4,"symbolHeight":14,"borderWidth":0,"symbolWidth":14,"align":"left","verticalAlign":"bottom","enabled":false},"tooltip":{"backgroundColor":"rgba(0,0,0,0)","useHTML":true,"borderWidth":0,"borderColor":"rgba(0,0,0,0)","padding":0,"shadow":null,"headerFormat":"","footerFormat":"","pointFormat":"<div class=\"flexccc lineHeight2 bgwhite shadow2 px3 py3 radiismall fonth10_semibold\">\n                <span class=\"colorgray-3 mb4\">{point.date:%b %d ,%Y}</span>\n                <span>Analyst Consensus</span>\n                {point.info}\n          </div>\n           </div>"},"credits":{"enabled":false},"accessibility":{"description":""},"responsive":{"rules":[{"chartOptions":{"chart":{"spacing":[0,0,0,0],"margin":[30,60,40,5]},"xAxis":{"tickPositions":[3,12,25.25]},"yAxis":{"labels":{"enabled":false}},"title":{"text":null},"subtitle":{"text":null}},"condition":{"maxWidth":500}}]},"series":[{"lineWidth":2,"dashStyle":"ShortDash","name":"High","type":"line","color":"#199ca5","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,4.49,5.683076923076923,6.876153846153846,8.06923076923077,9.262307692307694,10.455384615384617,11.64846153846154,12.841538461538462,14.034615384615385,15.227692307692308,16.42076923076923,17.613846153846154,18.806923076923077,{"y":20,"marker":{"fillColor":"#199ca5","lineColor":"#199ca5","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Average","type":"line","color":"#828080","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,4.49,5.4907692307692315,6.491538461538462,7.492307692307692,8.493076923076924,9.493846153846155,10.494615384615386,11.495384615384616,12.496153846153847,13.496923076923078,14.49769230769231,15.49846153846154,16.49923076923077,{"y":17.5,"marker":{"fillColor":"#828080","lineColor":"#828080","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Low","type":"line","color":"#912767","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,4.49,5.298461538461539,6.106923076923077,6.915384615384616,7.723846153846154,8.532307692307693,9.340769230769231,10.149230769230769,10.957692307692309,11.766153846153847,12.574615384615385,13.383076923076922,14.191538461538462,{"y":15,"marker":{"fillColor":"#912767","lineColor":"#912767","enabled":true,"symbol":"circle"}}]},{"type":"line","data":[{"y":5.5,"date":1722470400000,"info":"<div class=\"mt2 colorgray-1\">\n          No historical consensus available\n      </div>","marker":{"enabled":true,"symbol":"circle"}},{"y":5.5,"date":1725148800000,"info":"<div class=\"mt2 colorgray-1\">\n          No historical consensus available\n      </div>","marker":{"enabled":true,"symbol":"circle"}},{"y":5.5,"date":1727740800000,"info":"<div class=\"mt2 colorgray-1\">\n          No historical consensus available\n      </div>","marker":{"enabled":true,"symbol":"circle"}},{"y":5.5,"date":1730419200000,"info":"<div class=\"mt2 colorgray-1\">\n          No historical consensus available\n      </div>","marker":{"enabled":true,"symbol":"circle"}},{"y":5.5,"date":1733011200000,"info":"<div class=\"mt2 colorgray-1\">\n          No historical consensus available\n      </div>","marker":{"enabled":true,"symbol":"circle"}},{"y":5.58,"date":1735689600000,"info":"<div class=\"mt2 colorgray-1\">\n          No historical consensus available\n      </div>","marker":{"enabled":true,"symbol":"circle"}},{"y":5.58,"date":1735689600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 4,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":7,"date":1740787200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 8,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":3.4,"date":1743465600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 9,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":4.63,"date":1748736000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 7,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":3.07,"date":1754006400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 5,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":4.25,"date":1759276800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 5,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 5, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":4.49,"date":1761955200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 7,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 7, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 2</span>\n      ","marker":{"fillColor":"black","lineColor":"black","enabled":true,"symbol":"circle"}},null,null,null,null,null,null,null,null,null,null,null,null],"color":"#0666a7"}]}

Detailed Analyst Forecast >